Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity
The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...
Hematologic Malignancies Drive In-Hospital Death Rates
In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More
Remembering Milton H. Freedman (1919 – 2019)
Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21,...
Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...
The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...
Federal Trade Commission Wins Case Against Predatory Publisher
OMICS International, which publishes nearly 700 scientific journals, was ordered to pay $50.1 million in damages for engaging in “predatory publisher” tactics. The ruling...
Europe Poised to Approve Gene Therapy for Beta Thalassemia
Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended that the European Medicines Agency (EMA) approve Bluebird Bio’s LentiGlobin gene-therapy product for patients...
U.S. CRISPR Study in Humans Gets Underway
The first patients enrolled in a trial of CRISPR-based gene editing at the University of Pennsylvania have been treated with the powerful – and...
FDA and State Authorities Renew Efforts Against Dangerous Stem Cell Clinics
The U.S. Food and Drug Administration (FDA) and New York’s attorney general have announced new policing strategies against for-profit clinics that offer expensive and...
Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?
The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...
No Benefit in Adding Rituximab to MBVP in CNS Lymphoma
Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemotherapy...
Current Issue
June 2019, Volume 5, Issue 7
This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.
